|Compound||Status||ROS modulation||Clinical Trials|
|Arsenic trioxide (As2O3, trisenox)||FDA-approved for the treatment of relapsing AML.||
Inhibits MRC, TrxR and SOD; induces the expression of Nox2 complex genes and depletes Prx III
Phase II study of As2O3 plus decitabine and cytarabine AML with p53 mutations (NCT03381781, not yet recruiting).|
Phase I studies of As2O3 plus decitabine (NCT00671697, completed in 2011), plus cytarabine and idarubicin (NCT00093483, completed in 2009) for AML treatment.
Phase II/III study of As2O3 plus altezumab and other chemoteraputic agents for AML or MDS treatment (NCT00454480, completed).
|Metformin||FDA-approved for the treatment of type 2 diabetes.||
Inhibits mitochondrial ATP production
Phase II study for CLL treatment (NCT01750567, recruiting).|
Phase I study of metformin plus ritonavir for relapsed/refractory MM or CLL treatment (NCT02948283, active).
Phase I study for relapsed childhood ALL (NCT01324180; completed).
Phase I study of metformin plus cytarabine for relapsed/refractory AML treatment (NCT01849276, active).
|Tigecycline||FDA-approved for complicated skin and intra-abdominal infections.||
Inhibits mitochondrial biogenesis
Phase I study for AML treatment (NCT01332786, completed in 2015).|
In vitro study of tigecycline in cells from CML patients (NCT02883036, not yet recruiting).
|NOV-002||Under clinical trial.||
|Phase III study of NOV-002 plus cis-platinum and placlitaxel for NSCLC treatment (NCT00347412, completed in 2010).|
|2-methoxyestradiol (2-ME, panzem)||FDA-approved for ovarian cancer, metastatic malignant melanoma, MM and pancreatic adenocarcinoma.||
|Phase II study for the treatment of relapse or plateau phase myeloma (NCT00592579, completed in 2008).|
|Imexon||FDA-approved for pulmonary arterial hypertension, ovarian cancer, multiforme glioblastoma and MM treatment.||
GSH pool depletion
Phase I/II study in MM (NCT00327249, completed in 2008).|
Phase II study for the treatment of aggressive lymphomas (NCT01314014, completed in 2014).
|ATN-224||Under clinical trial.||
|Phase I/II study of ATN-224 plus bortezomib in MM patients (NCT00352742, completed in 2008).|
|PX-12||Under clinical trial.||
Thioredoxin system inhibitor
|Phase I (NCT00736372, completed in 2009) and phase II studies (NCT00417287, completed in 2009) against solid tumours.|
|Phenethyl isothiocyanate (PEITC)||Under clinical trial.||
Export GSH outside of the cell and inhibits GPx
Phase I study for preventing lung cancer (NCT00005883, completed).|
PEITC as support care in head and neck cancer patients (NCT03034603, recruiting).
|GKT137831||Under clinical trial.||
NOX1 and NOX4 inhibitor
|Phase II study for the treatment of patient with type 2 diabetes (NCT02010242, completed in 2015).|
|Allopurinol||FDA-approved for gout treatment and as prophylaxis treatment to prevent chemotherapy-induced uric acid elevation.||
|Phase II study of allopurinol in pediatric ALL treatment to improve 6-mercaptopurine treatment (NCT03022747, recruiting).|